about
Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.Strong correlation between protein reagent strip and protein-to-creatinine ratio for detection of renal dysfunction in HIV-infected patients: a cross-sectional studyEffectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patientsCorrelation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study.Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.Anal intraepithelial neoplasia among HIV-positive men who have sex with men.Development and validation of a questionnaire to identify patients with sleep apnea in Mexican population: Mexican questionnaire to identify sleep apnea.Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients.Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.Presence of rare hepatitis C virus subtypes, 2j, 2k, and 2r in Mexico City as identified by sequencing.Mexican patients with HIV have a high prevalence of vertebral fractures.Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvirProximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in MexicoThe Mexican consensus on the treatment of hepatitis C
P50
Q33421213-819EFD6B-A5B5-422A-9DC7-7FAD20C7E707Q35201114-4ADCDAB5-19CB-47FB-9A60-2FA13B6ABF13Q36091962-3480FB7B-D9FF-4408-B1C4-791C07768BDBQ37420583-B0477342-2E66-4E60-B7AB-76A09D02B08AQ37653463-911886D2-D79E-48C2-A7A1-8368A278D22CQ39901450-FD1BAC36-3F97-48B8-A9F8-44F5A21FDE0AQ40519652-817BE5C1-E3C4-4F13-A041-4C86C2A73129Q40628910-9E038930-C27D-488E-AA59-19B9511EFD84Q41003468-908A4099-9E3A-4D7E-83C1-6EADC065BD9CQ46858965-64DC2FC5-2860-44C8-AD60-3821D9948872Q48513490-85D7C545-B069-4DDD-AB0A-0BF3EA54ED00Q51519435-E11B582F-401A-44B8-94FE-6EA106815631Q52672285-D7F5B4CF-1865-4631-A6A9-8DB41790C653Q54222374-AE826359-A92B-4379-96A7-25856FC69D94Q59360837-4013EF2E-50FE-474E-9491-45D49CBE8641Q87518496-C627683E-F61A-4AC0-AFA8-7ED558310E42Q88870950-2593292F-4280-4643-A5D9-644330CBCCFB
P50
description
investigador
@es
researcher
@en
name
José Antonio Mata-Marín
@en
type
label
José Antonio Mata-Marín
@en
prefLabel
José Antonio Mata-Marín
@en
P31
P496
0000-0003-1329-7811